Wednesday, November 26, 2014
Inquirer Daily News

GlaxoSmithKline's China troubles not going away anytime soon

China's Security Ministry said Thursday that several GlaxoSmithKline executives based in the country had confessed to charges of bribery and tax law violations, Reuters reported.

GlaxoSmithKline's China troubles not going away anytime soon

China's Security Ministry said Thursday that several GlaxoSmithKline executives based in the country had confessed to charges of bribery and tax law violations, Reuters reported. Link here.

The bribes were offered to Chinese government officials, medical associations, hospitals and doctors to boost sales and prices, the ministry said in a statement on its website, according to Reuters.

GSK declined to comment on the number or nationality of the staff members involved.

"We take all allegations of bribery and corruption seriously," GSK said in a statement. "We continuously monitor our businesses to ensure they meet our strict compliance procedures - we have done this in China and found no evidence of bribery or corruption of doctors or government officials."

GSK is based in London, but has operations at Philadelphia's Navy Yard and in the region's suburbs.

Some of the trouble relates to sale of Botox, the skin enhancement medication. Allergan makes Botox and in 2005 struck a deal with GSK to market the drug in China.

 

David Sell
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Business Videos:
Also on Philly.com:
Stay Connected